Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present updated clinical data from a Phase Ib/II clinical study of its novel Nectin-4-targeting ADC 9MW2821 in combination with toripalimab, with or without bevacizumab, as a first-line treatment for cervical cancer, in an oral presentation at the ESMO Asia Congress 2026, which will be held in Singapore from December 4 to 6, 2026.

Oral Presentation

Abstract Title:
Bulumtatug Fuvedotin (BFv, 9MW2821) plus Toripalimab with or without Bevacizumab as First-Line Treatment for patients with persistent, recurrent, or metastatic cervical cancer: Updated Results from a Phase Ib/II Clinical Study

Final Publication Number:  476RO

Principal Investigator:
Prof. LOU Hanmei, Zhejiang Cancer Hospital
Prof. WANG Yudong, International Peace Maternity and Child Health Hospital of China Welfare Institute

Speaker:
Prof. Lou Hanmei, Zhejiang Cancer Hospital

Session: Gynaecological cancers

Date and Time: 12/6/2026, 9:55AM -10:00 AM (local time)

Location: Hall 405